One of the ongoing clinical trials is analysing the combination of a BRAF inhibitor—encorafenib—and a MEK inhibitor—binimetinib—for the treatment of PC in patients with the BRAF V600E mutation (NCT04390243). Here, MAP2K7 is linked to pachyonychia congenita.